Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (21-30 of 250) with videos related to

Pageof 25
Sort By:
Chinese Clinical Oncology|July 12, 2022
Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative reviewJaewon Hyung, Sang Soo Lee, Dae Wook Hwang, et al.
EJNMMI Physics|February 5, 2024
Prediction of [<sup>177</sup>Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [<sup>177</sup>Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumourSejin Ha, Yong-Il Kim, Jungsu S Oh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2015
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, et al.
Anticancer Research|April 27, 2024
CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in <i>KRAS</i> Mutant Cholangiocarcinoma Cell LinesDA Sol Lee, Min Woo Han, Yonghyun Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2024
Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal TumorsHyung-Don Kim, Min-Hee Ryu, Young Soo Park, et al.
The Oncologist|May 1, 2019
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and SunitinibJae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, et al.
British Journal of Cancer|May 13, 2016
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysisChanghoon Yoo, Min-Hee Ryu, Young-Soon Na, et al.
Cancers|June 2, 2021
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert OpinionSadahisa Ogasawara, Su-Pin Choo, Jiang-Tao Li, et al.
European Radiology|October 22, 2024
Prognostic value of interim [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapyEonwoo Shin, Yong-Il Kim, Changhoon Yoo, et al.
Clinical Nuclear Medicine|May 24, 2021
Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysisSangwon Han, Hyo Sang Lee, Sungmin Woo, et al.
Pageof 25

Showing results (21-30 of 250) with videos related to

Sort By:
Pageof 25
Chinese Clinical Oncology|July 12, 2022
Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative reviewJaewon Hyung, Sang Soo Lee, Dae Wook Hwang, et al.
EJNMMI Physics|February 5, 2024
Prediction of [<sup>177</sup>Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [<sup>177</sup>Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumourSejin Ha, Yong-Il Kim, Jungsu S Oh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2015
Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, et al.
Anticancer Research|April 27, 2024
CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in <i>KRAS</i> Mutant Cholangiocarcinoma Cell LinesDA Sol Lee, Min Woo Han, Yonghyun Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2024
Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal TumorsHyung-Don Kim, Min-Hee Ryu, Young Soo Park, et al.
The Oncologist|May 1, 2019
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and SunitinibJae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, et al.
British Journal of Cancer|May 13, 2016
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysisChanghoon Yoo, Min-Hee Ryu, Young-Soon Na, et al.
Cancers|June 2, 2021
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert OpinionSadahisa Ogasawara, Su-Pin Choo, Jiang-Tao Li, et al.
European Radiology|October 22, 2024
Prognostic value of interim [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapyEonwoo Shin, Yong-Il Kim, Changhoon Yoo, et al.
Clinical Nuclear Medicine|May 24, 2021
Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysisSangwon Han, Hyo Sang Lee, Sungmin Woo, et al.
Pageof 25